Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.78 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.55 |
| ▸ | PHGDH | O43175 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8131351 | 0.87 | MEN1 (0.73) | MEN1KMT2ARAB9AGAANPC1 | |
| SCHEMBL29505672 | 0.87 | MEN1 (0.73) | MEN1KMT2ARAB9AGAANPC1 | |
| SCHEMBL9185887 | 0.87 | MEN1 (0.78) | MEN1KMT2ARAB9AGAANPC1 | |
| SCHEMBL2966042 | 0.84 | ALDH1A1 (0.66) | MEN1KMT2ARAB9AGAANPC1 | |
| SCHEMBL18765120 | 0.84 | RAB9A (0.71) | MEN1KMT2ARAB9AGAANPC1 | |
| SCHEMBL29505687 | 0.84 | RAB9A (0.71) | MEN1KMT2ARAB9AGAANPC1 | |
| SCHEMBL4002217 | 0.83 | MEN1 (0.78) | MEN1KMT2ARAB9AGAANPC1 | |
| SCHEMBL6114931 | 0.83 | KMT2A (0.78) | MEN1KMT2ARAB9AGAANPC1 | |
| SCHEMBL14202813 | 0.83 | MEN1 (0.78) | MEN1KMT2ARAB9AGAANPC1 | |
| SCHEMBL1086054 | 0.83 | KMT2A (0.78) | MEN1KMT2ARAB9AGAANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017479-B2 | Process to make non nucleosidal reverse transcriptase inhibitors (NNRTI) for the treatment of HIV | ROSOCHA GREGORY (CA) | 2018-07-10 | — | — | US | disclosed |
| US-20160130238-A1 | New Process to make non nucleosidal reverse transcriptase inhibitors (NNRTI) for the treatment of HIV | ROSOCHA GREGORY (CA) | 2016-05-12 | — | — | US | disclosed |
| WO-2015015240-A1 | NEW PROCESS TO MAKE NON-NUCLEOSIDAL REVERSE TRANSCRIPTASE INHIBITORS (NNRTI) FOR THE TREATMENT OF HIV | ROSOCHA GREGORY (CA) | 2015-02-05 | — | — | WO | disclosed |
| EP-1569919-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2012-04-18 | — | — | EP | disclosed |
| EP-1569919-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2012-04-18 | — | — | EP | disclosed |
| US-7642277-B2 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-05 | — | — | US | disclosed |
| US-7642277-B2 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-05 | — | — | US | disclosed |
| US-7642277-B2 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-05 | — | — | US | disclosed |
| WO-2005115147-A2 | HIV REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2005-12-08 | — | — | WO | disclosed |
| US-20050054639-A1 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-03-10 | — | — | US | disclosed |
| WO-2003026666-A1 | 2-PHENYLAMINO-4- (5-PYRAZOLYLAMINO)-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS, IN PARTICULAR, AS SRC KINASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10017479-B2 | Process to make non nucleosidal reverse transcriptase inhibitors (NNRTI) for the treatment of HIV | DNTT, NNMT, PNP | MEN1 4680/4885KMT2A 480/4885RAB9A 4543/4885 |
| US-20050054639-A1 | Non-nucleoside reverse transcriptase inhibitors | NAT1, SUB1, RTF2 | MEN1 4841/4885KMT2A 895/4885RAB9A 4206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.